ELAVL1 and familial pancreatic carcinoma: dCK protein expression positively correlates with HuR protein levels and efficacy of gemcitabine, accordingly overexpression of HuR elevates, while silencing of HuR reduces dCK protein expression, conferring corresponding gemcitabine responses in pancreatic cancer cells.